Cargando…
Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study
BACKGROUND: Ovarian toxicity is a dreaded complication of cyclophosphamide (CYC). With the use of lower cumulative doses of intravenous CYC (modified NIH regimens) and availability of better markers of ovarian toxicity, the incidence of ovarian dysfunction needs reassessment. Lupus disease activity,...
Autores principales: | Sharma, Shefali Khanna, Jain, Siddharth, Bahl, Pooja, Potturi, Pragna, Rathi, Manish, Naidu, Shankar, Sachdeva, Naresh, Dhir, Varun, Jain, Sanjay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429750/ https://www.ncbi.nlm.nih.gov/pubmed/32799907 http://dx.doi.org/10.1186/s13075-020-02292-y |
Ejemplares similares
-
Analysis of the Clinical Effects of the Combination of Mycophenolate Mofetil with Either Tacrolimus or Cyclophosphamide
por: Zhang, Xuebing, et al.
Publicado: (2020) -
Predictors of COVID-19 severity and outcomes in Indian patients with rheumatic diseases: a prospective cohort study
por: Mathew, Jithin, et al.
Publicado: (2023) -
Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy
por: Bharati, Joyita, et al.
Publicado: (2018) -
Ciclosporin/cyclophosphamide/mycophenolate mofetil: Bacterial, viral and fungal infections: 71 case reports
Publicado: (2019) -
Mycophenolate or Cyclophosphamide in Lupus Nephritis: Which One to Use in Indian Patients?
por: Rathi, Manish, et al.
Publicado: (2018)